Stock Track | AB&B Bio-Tech Soars 35% as Flagship Flu Vaccine Shortlisted for China's Insurance Coverage

Stock Track

Aug 13

AB&B Bio-Tech (HKG:02627) saw its stock price skyrocket by 35.01% in intraday trading on Wednesday, following a significant announcement regarding its flagship flu vaccine. The Hong Kong-listed pharmaceutical company revealed that Chinese authorities have placed its quadrivalent subunit influenza vaccine, Huierkangxin, on a preliminary list for possible insurance coverage.

According to a Hong Kong bourse filing, AB&B Bio-Tech's Huierkangxin vaccine has been included in the National Healthcare Security Administration's preliminary list for insurance reimbursement. Notably, it is the only product of its kind to achieve this status, potentially giving the company a significant edge in the Chinese market. This development could lead to increased accessibility and demand for the vaccine, potentially boosting the company's revenue and market share.

Adding to the significance of this news, AB&B Bio-Tech stated that Huierkangxin remains the first and only quadrivalent subunit influenza vaccine to be approved in China as of July 21. This unique position in the market, combined with the possibility of insurance coverage, has evidently sparked investor enthusiasm, driving the stock's dramatic rise. The company's shares had already jumped 13% in Wednesday morning trade before the larger surge, indicating strong market confidence in AB&B Bio-Tech's future prospects based on this development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1130107646"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130107646\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130107646?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130107646","market":"nz","top_or_hot":-1,"title":"Stock Track | AB&B Bio-Tech Soars 35% as Flagship Flu Vaccine Shortlisted for China's Insurance Coverage","media":"Stock Track","content":"<p>AB&B Bio-Tech (HKG:02627) saw its stock price skyrocket by 35.01% in intraday trading on Wednesday, following a significant announcement regarding its flagship flu vaccine. The Hong Kong-listed pharmaceutical company revealed that Chinese authorities have placed its quadrivalent subunit influenza vaccine, Huierkangxin, on a preliminary list for possible insurance coverage.</p>\n\n<p>According to a Hong Kong bourse filing, AB&B Bio-Tech's Huierkangxin vaccine has been included in the National Healthcare Security Administration's preliminary list for insurance reimbursement. Notably, it is the only product of its kind to achieve this status, potentially giving the company a significant edge in the Chinese market. This development could lead to increased accessibility and demand for the vaccine, potentially boosting the company's revenue and market share.</p>\n\n<p>Adding to the significance of this news, AB&B Bio-Tech stated that Huierkangxin remains the first and only quadrivalent subunit influenza vaccine to be approved in China as of July 21. This unique position in the market, combined with the possibility of insurance coverage, has evidently sparked investor enthusiasm, driving the stock's dramatic rise. The company's shares had already jumped 13% in Wednesday morning trade before the larger surge, indicating strong market confidence in AB&B Bio-Tech's future prospects based on this development.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AB&B Bio-Tech Soars 35% as Flagship Flu Vaccine Shortlisted for China's Insurance Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AB&B Bio-Tech Soars 35% as Flagship Flu Vaccine Shortlisted for China's Insurance Coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-13 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AB&B Bio-Tech (HKG:02627) saw its stock price skyrocket by 35.01% in intraday trading on Wednesday, following a significant announcement regarding its flagship flu vaccine. The Hong Kong-listed pharmaceutical company revealed that Chinese authorities have placed its quadrivalent subunit influenza vaccine, Huierkangxin, on a preliminary list for possible insurance coverage.</p>\n\n<p>According to a Hong Kong bourse filing, AB&B Bio-Tech's Huierkangxin vaccine has been included in the National Healthcare Security Administration's preliminary list for insurance reimbursement. Notably, it is the only product of its kind to achieve this status, potentially giving the company a significant edge in the Chinese market. This development could lead to increased accessibility and demand for the vaccine, potentially boosting the company's revenue and market share.</p>\n\n<p>Adding to the significance of this news, AB&B Bio-Tech stated that Huierkangxin remains the first and only quadrivalent subunit influenza vaccine to be approved in China as of July 21. This unique position in the market, combined with the possibility of insurance coverage, has evidently sparked investor enthusiasm, driving the stock's dramatic rise. The company's shares had already jumped 13% in Wednesday morning trade before the larger surge, indicating strong market confidence in AB&B Bio-Tech's future prospects based on this development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"","article_id":"1130107646","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130107646","pubTimestamp":1755049962,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AB&B Bio-Tech (HKG:02627) saw its stock price skyrocket by 35.01% in intraday trading on Wednesday, following a significant announcement regarding its flagship flu vaccine. The Hong Kong-listed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"个股追踪|AB&B Bio-Tech飙升35%旗舰流感疫苗入围中国保险范围","themeId":"eea96c2db952be4ad0141d428041d6b9","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":1},"content_text":"AB&B Bio-Tech (HKG:02627) saw its stock price skyrocket by 35.01% in intraday trading on Wednesday, following a significant announcement regarding its flagship flu vaccine. The Hong Kong-listed pharmaceutical company revealed that Chinese authorities have placed its quadrivalent subunit influenza vaccine, Huierkangxin, on a preliminary list for possible insurance coverage.\nAccording to a Hong Kong bourse filing, AB&B Bio-Tech's Huierkangxin vaccine has been included in the National Healthcare Security Administration's preliminary list for insurance reimbursement. Notably, it is the only product of its kind to achieve this status, potentially giving the company a significant edge in the Chinese market. This development could lead to increased accessibility and demand for the vaccine, potentially boosting the company's revenue and market share.\nAdding to the significance of this news, AB&B Bio-Tech stated that Huierkangxin remains the first and only quadrivalent subunit influenza vaccine to be approved in China as of July 21. This unique position in the market, combined with the possibility of insurance coverage, has evidently sparked investor enthusiasm, driving the stock's dramatic rise. The company's shares had already jumped 13% in Wednesday morning trade before the larger surge, indicating strong market confidence in AB&B Bio-Tech's future prospects based on this development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}